Comment on: Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis by Humby et al

Affiliations

¹ Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey. docemineduran@gmail.com.
² Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Ankara, Turkey.
³ Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey.

Free article

Comment

Emine Duran et al. Clin Exp Rheumatol. 2023 Sep.

Free article

. 2023 Sep;41 Suppl 135(9):8.

doi: 10.55563/clinexprheumatol/85mraz. Epub 2021 Sep 7.

¹ Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey. docemineduran@gmail.com.
² Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Ankara, Turkey.
³ Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey.

No abstract available

Comment on

Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial.
Humby F, Durez P, Buch MH, Lewis MJ, Rizvi H, Rivellese F, Nerviani A, Giorli G, Mahto A, Montecucco C, Lauwerys B, Ng N, Ho P, Bombardieri M, Romão VC, Verschueren P, Kelly S, Sainaghi PP, Gendi N, Dasgupta B, Cauli A, Reynolds P, Cañete JD, Moots R, Taylor PC, Edwards CJ, Isaacs J, Sasieni P, Choy E, Pitzalis C; R4RA collaborative group. Humby F, et al. Lancet. 2021 Jan 23;397(10271):305-317. doi: 10.1016/S0140-6736(20)32341-2. Lancet. 2021. PMID: 33485455 Free PMC article. Clinical Trial.